Cargando…
Mo1018: THE T-CELL RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS OFTEN DEFICIENT IN ANTIBODY-RESPONDERS, AND AUGMENTED BY ANTI-TNF THERAPY
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
AGA Institute. Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212389/ http://dx.doi.org/10.1016/S0016-5085(22)61583-X |
| _version_ | 1784730576497934336 |
|---|---|
| author | Li, Dalin Xu, Alexander Elyanow, Rebecca Gittelman, Rachel M. Chapman, Heidi Prostko, John Pozdnyakova, Valeriya Debbas, Philip Mujukian, Angela Horizon, Arash A. Sobhani, Kimia Cheng, Susan Kaplan, Ian M. Mcgovern, Dermot P.B. Merchant, Akil Melmed, Gil Braun, Jonathan G. |
| author_facet | Li, Dalin Xu, Alexander Elyanow, Rebecca Gittelman, Rachel M. Chapman, Heidi Prostko, John Pozdnyakova, Valeriya Debbas, Philip Mujukian, Angela Horizon, Arash A. Sobhani, Kimia Cheng, Susan Kaplan, Ian M. Mcgovern, Dermot P.B. Merchant, Akil Melmed, Gil Braun, Jonathan G. |
| author_sort | Li, Dalin |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9212389 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | AGA Institute. Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92123892022-06-22 Mo1018: THE T-CELL RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS OFTEN DEFICIENT IN ANTIBODY-RESPONDERS, AND AUGMENTED BY ANTI-TNF THERAPY Li, Dalin Xu, Alexander Elyanow, Rebecca Gittelman, Rachel M. Chapman, Heidi Prostko, John Pozdnyakova, Valeriya Debbas, Philip Mujukian, Angela Horizon, Arash A. Sobhani, Kimia Cheng, Susan Kaplan, Ian M. Mcgovern, Dermot P.B. Merchant, Akil Melmed, Gil Braun, Jonathan G. Gastroenterology AGA Abstracts AGA Institute. Published by Elsevier Inc. 2022-05 2022-06-16 /pmc/articles/PMC9212389/ http://dx.doi.org/10.1016/S0016-5085(22)61583-X Text en Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | AGA Abstracts Li, Dalin Xu, Alexander Elyanow, Rebecca Gittelman, Rachel M. Chapman, Heidi Prostko, John Pozdnyakova, Valeriya Debbas, Philip Mujukian, Angela Horizon, Arash A. Sobhani, Kimia Cheng, Susan Kaplan, Ian M. Mcgovern, Dermot P.B. Merchant, Akil Melmed, Gil Braun, Jonathan G. Mo1018: THE T-CELL RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS OFTEN DEFICIENT IN ANTIBODY-RESPONDERS, AND AUGMENTED BY ANTI-TNF THERAPY |
| title | Mo1018: THE T-CELL RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS OFTEN DEFICIENT IN ANTIBODY-RESPONDERS, AND AUGMENTED BY ANTI-TNF THERAPY |
| title_full | Mo1018: THE T-CELL RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS OFTEN DEFICIENT IN ANTIBODY-RESPONDERS, AND AUGMENTED BY ANTI-TNF THERAPY |
| title_fullStr | Mo1018: THE T-CELL RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS OFTEN DEFICIENT IN ANTIBODY-RESPONDERS, AND AUGMENTED BY ANTI-TNF THERAPY |
| title_full_unstemmed | Mo1018: THE T-CELL RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS OFTEN DEFICIENT IN ANTIBODY-RESPONDERS, AND AUGMENTED BY ANTI-TNF THERAPY |
| title_short | Mo1018: THE T-CELL RESPONSE TO SARS-COV-2 VACCINATION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IS OFTEN DEFICIENT IN ANTIBODY-RESPONDERS, AND AUGMENTED BY ANTI-TNF THERAPY |
| title_sort | mo1018: the t-cell response to sars-cov-2 vaccination in patients with inflammatory bowel disease is often deficient in antibody-responders, and augmented by anti-tnf therapy |
| topic | AGA Abstracts |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9212389/ http://dx.doi.org/10.1016/S0016-5085(22)61583-X |
| work_keys_str_mv | AT lidalin mo1018thetcellresponsetosarscov2vaccinationinpatientswithinflammatoryboweldiseaseisoftendeficientinantibodyrespondersandaugmentedbyantitnftherapy AT xualexander mo1018thetcellresponsetosarscov2vaccinationinpatientswithinflammatoryboweldiseaseisoftendeficientinantibodyrespondersandaugmentedbyantitnftherapy AT elyanowrebecca mo1018thetcellresponsetosarscov2vaccinationinpatientswithinflammatoryboweldiseaseisoftendeficientinantibodyrespondersandaugmentedbyantitnftherapy AT gittelmanrachelm mo1018thetcellresponsetosarscov2vaccinationinpatientswithinflammatoryboweldiseaseisoftendeficientinantibodyrespondersandaugmentedbyantitnftherapy AT chapmanheidi mo1018thetcellresponsetosarscov2vaccinationinpatientswithinflammatoryboweldiseaseisoftendeficientinantibodyrespondersandaugmentedbyantitnftherapy AT prostkojohn mo1018thetcellresponsetosarscov2vaccinationinpatientswithinflammatoryboweldiseaseisoftendeficientinantibodyrespondersandaugmentedbyantitnftherapy AT pozdnyakovavaleriya mo1018thetcellresponsetosarscov2vaccinationinpatientswithinflammatoryboweldiseaseisoftendeficientinantibodyrespondersandaugmentedbyantitnftherapy AT debbasphilip mo1018thetcellresponsetosarscov2vaccinationinpatientswithinflammatoryboweldiseaseisoftendeficientinantibodyrespondersandaugmentedbyantitnftherapy AT mujukianangela mo1018thetcellresponsetosarscov2vaccinationinpatientswithinflammatoryboweldiseaseisoftendeficientinantibodyrespondersandaugmentedbyantitnftherapy AT horizonarasha mo1018thetcellresponsetosarscov2vaccinationinpatientswithinflammatoryboweldiseaseisoftendeficientinantibodyrespondersandaugmentedbyantitnftherapy AT sobhanikimia mo1018thetcellresponsetosarscov2vaccinationinpatientswithinflammatoryboweldiseaseisoftendeficientinantibodyrespondersandaugmentedbyantitnftherapy AT chengsusan mo1018thetcellresponsetosarscov2vaccinationinpatientswithinflammatoryboweldiseaseisoftendeficientinantibodyrespondersandaugmentedbyantitnftherapy AT kaplanianm mo1018thetcellresponsetosarscov2vaccinationinpatientswithinflammatoryboweldiseaseisoftendeficientinantibodyrespondersandaugmentedbyantitnftherapy AT mcgoverndermotpb mo1018thetcellresponsetosarscov2vaccinationinpatientswithinflammatoryboweldiseaseisoftendeficientinantibodyrespondersandaugmentedbyantitnftherapy AT merchantakil mo1018thetcellresponsetosarscov2vaccinationinpatientswithinflammatoryboweldiseaseisoftendeficientinantibodyrespondersandaugmentedbyantitnftherapy AT melmedgil mo1018thetcellresponsetosarscov2vaccinationinpatientswithinflammatoryboweldiseaseisoftendeficientinantibodyrespondersandaugmentedbyantitnftherapy AT braunjonathang mo1018thetcellresponsetosarscov2vaccinationinpatientswithinflammatoryboweldiseaseisoftendeficientinantibodyrespondersandaugmentedbyantitnftherapy |